Extracellular vesicle features are associated with COVID-19 severity

Area of Science:

• Immunology and Infectious Diseases
• Biomarker Discovery
• Extracellular Vesicle Biology

Background:

• COVID-19 presents heterogeneously, necessitating early identification of biomarkers for adverse outcomes.
• Extracellular vesicles (EVs) play a role in COVID-19 pathophysiology, with both beneficial and detrimental effects.
• Accurate prognostic stratification is crucial for managing severe and critical COVID-19 patients.

Purpose of the Study:

• To investigate the prognostic role of extracellular vesicles (EVs) in stratifying COVID-19 patients.
• To identify specific EV characteristics and clinical parameters associated with patient outcomes.

Main Methods:

• Enrolled 146 severe or critical COVID-19 patients, collecting demographic, comorbidity, and laboratory data.
• Performed flow cytometric characterization of plasma EV dimensions and antigenic properties.
• Utilized elastic net logistic regression with cross-validation for patient classification.

Main Results:

• Smaller EVs ( < 200 nm) expressing CD31, CD140b, or CD42b, along with albuminemia and monocyte HLA-DR, predicted better outcomes.
• Larger EVs expressing N-cadherin, CD34, CD56, CD31, or CD45, along with elevated IL-6, RDW, NT-proBNP, age, procalcitonin, CCI, and pro-ADM, correlated with disease severity.
• EV dimensions and antigenic properties, combined with laboratory workup, enhance patient stratification.

Conclusions:

• Simultaneous assessment of EV size and antigen expression provides valuable prognostic information for COVID-19 patients.
• This approach complements standard laboratory diagnostics for improved patient stratification and management.
• EV profiling offers a novel avenue for understanding COVID-19 severity and predicting clinical trajectories.